Results: The mean score of BASDAI was 4.20 ± 2.38. The mean scores of BASDAI were higher in patients with the combined (axial + peripheral + entheseal) (4.54 ± 2.38) clinical presentation, compared to the pure axial (3.78 ± 2.27) or pure peripheral (4.00 ± 2.38) clinical presentations (P < 0.001). BASDAI also presented higher scores associated with the female gender (P < 0.001) and patients who did not practice exercises (P < 0.001). Regarding the axial component, higher values of BASDAI were significantly associated with inflammatory low back pain (P < 0.049), alternating buttock pain (P < 0.001), cervical pain (P < 0.001) and hip involvement (P < 0.001). There was also statistical association between BASDAI scores and the peripheral involvement, related to the lower (P = 0.004) and upper limbs (P = 0.025). The presence of enthesitis was also associated to higher scores of BASDAI (P = 0.040). Positive HLA-B27 and the presence of cutaneous psoriasis, inflammatory bowel disease, uveitis and urethritis were not correlated with the mean scores of BASDAI. Lower scores of BASDAI were associated with the use of biologic agents (P < 0.001).
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Conclusion:
In this heterogeneous Brazilian series of SpA patients, BASDAI was able to demonstrate "disease activity" in patients with axial as well as peripheral disease.
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Introduction
The denomination spondyloarthritis (SpA) defines a heterogeneous group of diseases that share genetic and clinical characteristics, as well as structural changes in imaging studies. The positivity of HLA-B27 and the absence of rheumatoid factor are common to this group of diseases, and the high frequency of inflammatory processes of the spine, sacroiliac joints and enthesis is considered the main clinical criteria for the diagnosis of SpA. 1 Other clinical manifestations occur in varying degrees of involvement in the group of SpA; more often, skin, ocular, intestinal and urogenital injuries and, less frequently, pulmonary, cardiac, renal and neurological involvement. 1 This group of diseases consists of ankylosing spondylitis (AS), psoriatic arthritis (PA), reactive arthritis (ReA), arthritis associated with inflammatory bowel diseases (also known as enterophatic arthritis -EA) and undifferentiated spondyloarthritis (USpA). 1 With the advent of new therapeutic modalities for the group of SpA, the elaboration of measures of disease activity that could be used in long-term follow-up was necessary. 2 Currently, to evaluate and monitor clinical disease activity in SpA, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) has been used. This index is obtained by summing the values of a visual analog scale (VAS) that evaluates six items, namely: fatigue, axial pain, peripheral pain, enthesitis, duration and intensity of morning stiffness. 3 BASDAI does not use any marker of inflammatory activity in its calculation, since these tests were not standardized at the time of its proposition. 3 BASDAI values are internationally used (BAS-DAI ≥ 4 is deemed as "high disease activity") for the indication of biological agents in the treatment of SpA, when there was no response to conventional treatment with nonsteroidal antiinflammatory drugs or with conventional remissive drugs. 4, 5 When the patient reaches BASDAI 50 (improvement in the BASDAI score of ≥50%) in the first 12 weeks of treatment, this can be considered as a very good clinical response. 6 Due to its importance, BASDAI has been translated and validated in several languages, including French, 7 Swedish, 8 German, 9 Spanish, 10 Turkish, 11 Arabic 12 and Portuguese. 13 Recently, the Ankylosing Spondylitis Disease Activity Score (ASDAS) was created 14 ; this index associates the presence of a marker of inflammatory activity, erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP); nowadays, ASDAS has its cutoff scores to differentiate "moderate", "high" and "very high" activity. 15 This paper analyzes the application of BASDAI in a heterogeneous Brazilian cohort of 1492 patients with SpA.
Methods
This is a prospective, observational, multicenter study, conducted with 1492 patients from 29 referral centers participating in the Brazilian Registry of Spondyloarthritides (Registro Brasileiro de Espondiloartrites -RBE). All patients fulfilled the criteria of the European Spondyloarthropathy Study Group (ESSG). 16 The joint investigation protocol included demographic variables (gender, race, family history, HLA-B27, exercise), osteoarticular (inflammatory low back pain, buttock pain, neck pain, hip pain, lower limb arthritis, upper limb arthritis, enthesitis, dactylitis) and extra-articular (uveitis, inflammatory bowel disease [IBD], psoriasis, urethritis) disorders, and laboratory data (erythrocyte sedimentation rate -ESR and C-reactive protein -CRP), as well as the treatment (nonsteroid anti-inflammatory drugs -NSAIDs, corticosteroids and conventional and biological remissive drugs).
For the diagnosis of AS, the New York criteria were used 17 ; for psoriatic arthritis, the participants had to meet the criteria of Moll and Wright. 18 The diagnosis of reactive arthritis was considered if asymmetric oligoarthritis of the lower limbs were present, with enthesopathy and/or inflammatory low back pain arousing after an enteric or urogenital infection, 19 and spondyloarthritis/arthritis associated with inflammatory bowel disease, if the patient had an inflammatory axial disorder and/or peripheral joint involvement, associated with confirmed Crohn's disease or ulcerative colitis.
BASDAI is a tool for evaluation of disease activity that contains six questions. 3 The responses were marked on a horizontal line measuring 10 cm (from 0 to 10 cm), where the patient evaluates how he feels in relation to each item in the last week, marking on the scale: if the patient is fine ("very well"), he/she marks zero cm, gradually increasing until "very poor", corresponding to a 10-cm mark. The six questions comprising BASDAI are as follows: (1) How would you describe the degree of fatigue or tiredness you have had?; (2) How would you describe the overall level of neck, back and hip pain related to your illness?; (3) How would you describe the overall level of pain and edema (swelling) in other joints, apart from neck, back and hip?; (4) How would you describe the overall level of discomfort you felt to the touch or compression in the painful regions of your body?; (5) How would you describe the intensity of morning stiffness you have had, from the time you wake up?; (6) How long does your morning stiffness take, from the time you wake up?
Statistical analysis
The variable categories were compared using 2 and Fisher's exact tests, and continuous variables were compared using ANOVA. A value of P < 0.05 was considered significant; and 0.05 > P > 0.10 was considered as a statistical trend.
Results
The mean score of total BASDAI was 4.20 ± 2.38. Among the six items that make up the final value of BASDAI, the item 2 (related to axial pain; 5.05 ± 3.20) had the highest mean, and the item 3 (related to peripheral component; 3.28 ± 3.18) was that with the lowest value. The mean values of BASDAI to all the questions that make up the index are described in Table 1 . There was no significant difference between the mean values of BASDAI and any specific disease within the SpA group. The mean values of BASDAI for each disease within the group are shown in Table 2 . As to the clinical presentation, the mean values of BASDAI were significantly higher in enthesitic (4.96 ± 2.22) and combined (axial and peripheral; 4.50 ± 2.38) forms, compared to pure forms, both axial (3.78 ± 2.28) and peripheral (3.87 ± 2.23) ( Table 3) .
With regard to demographic variables, BASDAI was significantly higher in females (P < 0.001) and in those patients who did not exercise regularly (P < 0.001). Ethnicity, HLA-B27 and family history of SpA did not influence the results of BASDAI (Table 4) .
Numerous clinical variables influenced BASDAI scores. Inflammatory low back pain (P = 0.039), buttock pain (P < 0.001), neck pain (P < 0.001), hip pain (P < 0.001), arthritis of lower (P = 0.004) and upper (P = 0.025) limbs, and enthesitis (P = 0.040) were significantly associated with higher mean values of BAS-DAI. Extra-articular manifestations such as uveitis, psoriasis, inflammatory bowel disease and urethritis did not influence BASDAI scores (Table 5) . With regard to treatment, only the use of anti-TNF biological agents was significantly associated with lower scores of BASDAI (P < 0.001), while the use of NSAIDs, corticosteroids, methotrexate and sulfasalazine did not influence the values of BASDAI (Table 6) .
Discussion
This study aimed to evaluate the activity of SpA using BAS-DAI as a clinical activity index; this is a tool traditionally used in patients with SpA. The results showed that BASDAI could demonstrate "disease activity", both in patients with an axial component as in those with peripheral involvement, even in patients with SpA but with no diagnosis of AS. In view of the fact that BASDAI evaluate "axial" (question 2) and "peripheral" (questions 3 and 4) components, an important finding in this study was represented by the highest mean scores in patients who had an involvement described as "combined" (where the "axial" and "peripheral" components are observed in the same patient) -a common characteristic of Brazilian patients. 20 Similarly, an European multicenter 3) compared to patients with an isolated axial component (3.1 ± 1.9) (P < 0.001). 21 Also important was the fact that the mean values of BASDAI were significantly elevated, both in presence of axial (inflammatory low back pain, buttock pain, neck pain and hip pain) and peripheral (lower and upper joints) clinical variables, in addition to enthesitis. In the spectrum of SpA, psoriatic arthritis is that disease where the peripheral component is most striking. Our study showed that BASDAI can also be effective in the evaluation of patients with PA, as shown in recent studies, 22, 23 even when compared to ASDAS. 24 With the proposition of ASDAS as a valid method of assessing disease activity in cases of AS, 14, 15 it will be important to apply this tool to patients with SpA in the second phase of RBE, to compare its effectiveness versus BASDAI. There is no established consensus about what is the best method for assessment of disease activity in patients with AS (if ASDAS is better than BASDAI). Meanwhile, BASDAI has been shown as an efficient index in the therapeutic follow-up of patients with AS. 6, 25, 26 The combination of BASDAI with the functional index BASFI (Bath Ankylosing Spondylitis Disease Activity Index) 27 made it possible to obtain important characteristics of patients in the Brazilian Registry of Spondyloarthritides. 28 Although representing only 27.7% of the patients, women had higher mean BASDAI scores, when compared to men. These results certainly may vary with the population evaluated. 29 Regarding the skin color of the patients, there was no significant difference, as previously described, 30 and no significant difference in BASDAI scores in relation to HLA-B27, family history and extra-articular manifestations was found.
In short, BASDAI showed to be an efficient method of assessing disease activity in a heterogeneous population of Brazilian patients with SpA.
